Pharmacy News

DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology

   CUPERTINO, Calif., Aug. 27  — DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT’s patented ORADUR(TM) technology.... [Read more...]

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

CAMBRIDGE, Mass., Aug. 27 — Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week’s edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan... [Read more...]

National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births

   CHICAGO, Aug. 27  — Results of a 10-year study published in the August 28 issue of the New England Journal of Medicine found that magnesium sulfate administered to women delivering before 32 weeks of gestation reduced the risk of cerebral palsy by 50 percent. The Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) trial was conducted... [Read more...]

Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing

   FORT WORTH, Texas, Aug. 26 — Healthpoint today announced that it has initiated a clinical trial to evaluate the effectiveness of a widely prescribed enzymatic debriding agent on healing cutaneous wounds and resulting scars. The pilot study was prompted, in part, by clinical reports of the reduced incidence of hypertrophic scars and beneficial... [Read more...]

VYVANSE(R) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide in Six Dosage Strengths, Allowing Physicians to Titrate to Achieve Optimal Efficacy and Tolerability in Children and Adults with ADHD

BASINGSTOKE, U.K., and PHILADELPHIA, Aug. 26 – Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The expanded VYVANSE... [Read more...]

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

   ROCKVILLE, Md., Aug. 26 – Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax’s VLP candidate... [Read more...]

Read More Pharmacy News